<p>In patients with sepsis, the activation of the cascade systems, for example the complement system with the generation of C5a, is followed by a state of immunosuppression with impaired bactericidal capacity caused by suppression of the neutrophil granulocytes. To inhibit the C5a-induced systemic inflammatory and the following anti-inflammatory responses, different anti-C5a strategies have been successful in experimental models of sepsis. In animals and in healthy volunteers after injection of lipopolysaccharide (LPS), an up-regulation of the C5a receptor (C5aR) has been reported. Before designing clinical studies, it was of importance to increase the knowledge of C5a and C5aR regulation in humans. </p><p>At the time when the diagnosis of severe sepsis or septic shock can be established clinically, granulocyte C5aR expression, analysed by flow cytometer, was shown to be reduced, whereas monocyte C5aR expression was unchanged. There was a correlation between granulocyte C5aR expression and the severity of disease, as measured by the APACHE II score. </p><p><i>Ex vivo</i> incubation of whole blood with LPS resulted in a reduction in granulocyte C5aR expression. Such a reduction was not found in isolated cells, indicating that the effect was mediated via plasma factors, such as C5a, IL-8 and TNF-α which all were shown to reduce C5aR expression <i>ex vivo</i>.</p><p>Although there was a trend between chemotaxis, as measured by migration in a modified Boyden chamber, and C5aR expression on granulocytes from patients with severe sepsis or septic shock or from healthy individuals, the correlation failed to reach statistical significance.</p><p>It is concluded that granulocyte C5aR expression is affected by several plasma factors and that a reduction is clinically evident at the time of the sepsis diagnosis. Reduced granulocyte C5aR expression is associated with an impaired chemotaxis but does not alone limit the chemotactic response.</p>

In patients with sepsis, the activation of the cascade systems, for example the complement system with the generation of C5a, is followed by a state of immunosuppression with impaired bactericidal capacity caused by suppression of the neutrophil granulocytes. To inhibit the C5a-induced systemic inflammatory and the following anti-inflammatory responses, different anti-C5a strategies have been successful in experimental models of sepsis. In animals and in healthy volunteers after injection of lipopolysaccharide (LPS), an up-regulation of the C5a receptor (C5aR) has been reported. Before designing clinical studies, it was of importance to increase the knowledge of C5a and C5aR regulation in humans. At the time when the diagnosis of severe sepsis or septic shock can be established clinically, granulocyte C5aR expression, analysed by flow cytometer, was shown to be reduced, whereas monocyte C5aR expression was unchanged. There was a correlation between granulocyte C5aR expression and the severity of disease, as measured by the APACHE II score. Ex vivo incubation of whole blood with LPS resulted in a reduction in granulocyte C5aR expression. Such a reduction was not found in isolated cells, indicating that the effect was mediated via plasma factors, such as C5a, IL-8 and TNF-α which all were shown to reduce C5aR expression ex vivo. Although there was a trend between chemotaxis, as measured by migration in a modified Boyden chamber, and C5aR expression on granulocytes from patients with severe sepsis or septic shock or from healthy individuals, the correlation failed to reach statistical significance. It is concluded that granulocyte C5aR expression is affected by several plasma factors and that a reduction is clinically evident at the time of the sepsis diagnosis. Reduced granulocyte C5aR expression is associated with an impaired chemotaxis but does not alone limit the chemotactic response.

Nous avons identifié l’expression du récepteur des angiopoïétines, le récepteur Tie2, à la surface des neutrophiles humains. De plus, nous avons démontré qu’Ang1 et Ang2 induisent des activités pro-inflammatoires sur les neutrophiles, comme l’adhésion aux cellules endothéliales (CEs) et la synthèse du facteur d’activation plaquettaire (PAF). Puisque le PAF augmente la viabilité des neutrophiles et que les angiopoïétines modulent la survie des CEs, nous avons voulu évaluer l’effet des angiopoïétines sur la survie des neutrophiles. Des neutrophiles humains ont été isolés à partir du sang de donneurs sains en accord avec le comité d’éthique de l’Institut de cardiologie de Montréal. La viabilité des neutrophiles a été mesurée par cytométrie en flux à l’aide de marqueurs d’apoptose et de nécrose. Un traitement avec des témoins positifs, soit l’interleukine 8 (IL-8; 25 nM) ou le PAF (100 nM), a augmenté la survie basale des neutrophiles de 34 et 27%, respectivement. De plus, un traitement avec Ang1 (1 pM – 10 nM) a augmenté la survie des neutrophiles jusqu’à 35%, alors qu’Ang2 n’a eu aucun effet. La combinaison de l’IL-8 ou du PAF avec Ang1 (10 nM) a eu un effet additif sur la viabilité des neutrophiles et a augmenté la survie de 56 et 60%, respectivement. Un prétraitement avec des anticorps bloquants contre l’IL-8 a permis d’inhiber l’activité anti-apoptotique de l’IL-8 et d’Ang1 de 92 et 80%, respectivement. Ainsi, notre étude est la première à démontrer la capacité d’Ang1 à prolonger la viabilité des neutrophiles, qui est principalement causée par la relâche d’IL-8. / We reported the expression of angiopoietin receptor Tie2 on the surface of human neutrophils. In addition, we reported that Ang1 and Ang2 are both capable to promote pro-inflammatory activities in neutrophils, namely their adhesion onto endothelial cells (ECs) and platelet-activating factor (PAF) synthesis. PAF is known to promote pro-survival activity on neutrophils and since both angiopoietins can modulate ECs viability, we addressed whether Ang1 and/or Ang2 could modulate neutrophil viability. Human neutrophils were isolated from blood of healthy volunteers in accordance with the guidelines of the Montreal Heart Institute’s ethical committee. Neutrophil viability was assessed by flow cytometry using apoptotic and necrotic markers. Treatment with anti-apoptotic mediators such as interleukin 8 (IL-8; 25 nM) and PAF (100 nM) increased neutrophil basal viability by 34 and 27%, respectively. In addition, treatment with Ang1 (1 pM – 10 nM) increased neutrophil viability by up to 35%, while Ang2 had no effect. Combination of IL-8 or PAF with Ang1 (10 nM) provided an additive effect on neutrophil viability and further increased viability by 56 and 60%, respectively. Pretreatment of the neutrophils with blocking anti-IL-8 antibodies inhibited the anti-apoptotic effect of IL-8 and Ang1 by 92 and 80%, respectively. In summary, our data are the first one to report Ang1 pro-survival activity on neutrophils, which is mainly driven through IL-8 release.

Thesis (Ph. D.)--University of Alabama at Birmingham, 2008. / Title from first page of PDF file (viewed June 6, 2008). Includes bibliographical references.

Thesis (Ph. D.)--Ohio State University, 2007. / Title from first page of PDF file. Includes bibliographical references (p. 161-184).

Diss. (sammanfattning) Linköping : Linköpings universitet, 2009. / Härtill 4 uppsatser.

CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel Superior / A pitanga (Eugenia uniflora L.) à uma fruta tropical encontrada na regiÃo que compreende a parte central do Brasil e o Nordeste da Argentina. Este fruto possui baixo conteÃdo de lipÃdios, sendo rico em vitaminas e compostos bioativos, como os polifenÃis e carotenÃides. Devido ao uso da pitangueira na medicina popular e escassez de trabalhos cientÃficos sobre as propriedades antioxidantes e antiinflamatÃrias da pitanga roxa, o presente trabalho teve como objetivo investigar essas caracterÃsticas na polpa e no suco tropical de pitanga roxa adoÃado, usando experimentos in vitro e ex vivo. No presente estudo, a polpa de roxa foi separada em duas fraÃÃes (volÃtil e nÃo volÃtil), sendo o composto majoritÃrio de cada fraÃÃo identificado e quantificado. CÃlulas da gengiva humana (provenientes de seis voluntÃrios) foram expostas ao suco tropical de pitanga e ao composto majoritÃrio de cada fraÃÃo e analisadas quanto a atividade da catalase, o dano do DNA e a liberaÃÃo da interleucina 8 (IL-8). O experimento tambÃm foi realizado em cÃlulas dos fibroblastos gengivais humanos (HGF-1), cujas cÃlulas foram expostas aos compostos majoritÃrios das duas fraÃÃes da polpa de pitanga roxa e a liberaÃÃo da IL-8 foi analisada. A polpa de pitanga roxa apresentou valores mÃdios de sÃlidos solÃveis (8,33  0,06 ÂBrix), pH (3,12  0,01), acidez titulÃvel (1,76  0,20 g Ãcido cÃtrico/100 mL) e aÃÃcares totais (9,28  0,60 g glicose/100 mL) dentro dos padrÃes exigidos pela legislaÃÃo brasileira vigente. A referida polpa apresentou, ainda, nÃveis considerÃveis dos compostos bioativos: antocianinas (24,82  0,46 mg/100 mL), flavonÃides amarelos (11,33  0,66 mg/100 mL) e polifenÃis extraÃveis totais (26,85  0,30 mg GAE/100 mL), fazendo deste fruto uma boa fonte de antioxidantes naturais. Como composto majoritÃrio das fraÃÃes volÃtil e nÃo volÃtil da polpa de pitanga observa-se a oxidoselina-1,3,7(11)-trien-8-ona (85  4,01 Âg/mL) e a cianidina-3-glicosÃdeo (340  4,19 Âg/mL), respectivamente. O baixo pH do suco tropical de pitanga roxa adoÃado provocou uma reduÃÃo da atividade da catalase, enquanto a oxidoselina-1,3,7(11)-trien-8-ona e a cianidina-3-glicosÃdeo nÃo interferiram e nÃo foram capazes de inibir a atividade desta enzima. O suco tropical de pitanga roxa adoÃado preveniu o dano do DNA em cÃlulas da gengiva humana. Devido ao baixo nÃmero de voluntÃrios no experimento com o suco tropical de pitanga roxa adoÃado e os compostos majoritÃrios das fraÃÃes volÃtil e nÃo volÃtil da polpa de pitanga roxa, os resultados referentes à liberaÃÃo da IL-8 sÃo inconclusivos. Cianidina-3-glicosÃdeo e oxidoselina-1,3,7(11)-trien-8-ona apresentaram efeito antiinflamatÃrio em cÃlulas HGF-1. / Pitanga (Eugenia uniflora L.) is a tropical fruit found in the region that covers the central part of Brazil to Northern Argentina. This fruit has low lipid content, and is rich in bioactive compounds, such as polyphenols and carotenoids. In view of the use of pitanga tree in folk medicine and the shortage of scientific works about the antioxidative and anti-inflammatory effect of the purple pitanga, the present work aimed to investigate these characteristics in the pulp and in the sweetened tropical juice of purple pitanga, using in vitro and ex vivo experiments. In the present study, purple pitanga pulp was divided into two fractions (volatile and non-volatile), and the main compound of each fraction was identified and quantified. Human gingival cells (from six volunteers) were exposed to purple pitanga sweetened tropical juice and its main volatile and non-volatile compounds and analyzed by the catalase activity, DNA damage and interleukin 8 (IL-8) releases. The experiment was also performed with human gingival fibroblast (HGF-1), where cells were exposed to the individual main compounds from purple pitanga pulp and the IL-8 release was analyzed. Purple pitanga pulp presented mean values of soluble solids (8.33  0.06 ÂBrix), pH (3.12  0.01), titratable acidity (1.76  0.20 g citric acid/100 mL) and total sugars (9.28  0.60 g glucose/100 mL) within the standards required by current Brazilian law. This pulp also showed significant levels of the bioactive compounds: anthocyanins (24.82  0.46 mg/100 mL), yellow flavonoids (11.33  0.66 mg/100 mL) and total extractable polyphenols (26.85  0.30 mg GAE/100 mL), making this product a good source of natural antioxidants. With regard to the main compound from volatile and non-volatile fractions of purple pitanga pulp, oxidoselina-1,3,7(11)-trien-8-one (85  4.01 Âg/mL) was observed in the volatile fraction and cyanidin-3-glucoside (340  4.19 Âg/mL )was observed in the non-volatile fraction. The low pH of the purple pitanga sweetened tropical juice decreases catalase activity, while oxidoselina-1,3,7(11)-trien-8-one and cyanidin-3-glucoside did not interfere and were not able to inhibit the activity of this enzyme. Purple pitanga sweetened tropical juice prevented DNA damage in human gingival cells. Due to the low number of volunteers in the experiment with purple pitanga sweetened tropical juice and the main compounds from volatile and non-volatile fractions of purple pitanga pulp, the results regarding the IL-8 release are inconclusive. Cyanidin-3-glucoside and oxidoselina-1,3,7(11)-trien-8-one presented anti-inflammatory effects in HGF-1 cells.

L’invasion métastatique des tumeurs humaines est un mécanisme complexe qui repose sur l’acquisition de nouvelles fonctionnalités par les cellules tumorales. Les protéines ADAM et plus particulièrement la protéine ADAM9, grâce à leur domaine extracellulaire se composant d’une activité métalloprotéasique et disintégrine, possèdent des fonctions importantes et nécessaires au processus d’invasion. Cependant, les mécanismes de régulation de la protéine restent globalement méconnus dans la pathologie cancéreuse. L’objectif de ce travail a consisté à évaluer le rôle de l’expression d’ADAM9 dans les mécanismes d’agressivité tumorale tels que l’adhérence cellulaire, la migration cellulaire ou l’angiogénèse ainsi que l’étude des mécanismes de régulation de l’expression de cette protéine. Compte tenu du fait que le peroxyde d’hydrogène est connu pour induire l’expression d’ADAM9, les premiers travaux ont eu pour objectif d’établir le lien entre stress oxydant, ADAM9 et adhérence tumorale. L’exposition des cellules d’adénocarcinome pulmonaire au peroxyde d’hydrogène induit une augmentation dose dépendante de l’expression de la protéine ADAM9 transmembranaire et de sa forme sécrétée. Les études in vitro ont permis d’établir que les capacités d’adhérence et d’invasion tumorale induites par le stress oxydant sont principalement médiées par les deux isoformes de la protéine ADAM9. Par ailleurs, l’expression d’ADAM9 provoque un accroissement de la néo-angiogénèse par l’intermédiaire d’un accroissement non transcriptionel de la biosynthèse d’IL8. Cette cytokine proangiogénique va interagir avec le récepteur CXCR2 et va permettre la mise en place d’une néovascularisation in vitro. Le développement d’un modèle de xénogreffe de cellule d’adénocarcinome pulmonaire a permis de confirmer le rôle majeur d’ADAM9 dans les processus de dissémination métastatique et d’angiogénèse tumoraux. L’étude de la modulation pharmacologique d’ADAM9 a reposé sur deux stratégies pharmacologiques différentes : d’une part l’interaction directe avec les différentes isoformes d’ADAM9 au moyen d’un anticorps neutralisant et d’autre part une action sur les mécanismes de transduction cellulaire tels que la protéine SRC ou la protéine kinase C. Ce travail a permis de mieux comprendre l’implication de la protéine ADAM9 au cours du processus de cancérogenèse de part sa participation aux étapes majeures que sont la dissémination métastatique induite par le stress oxydant et l’angiogenèse / Tumor invasion is a complex mechanism that is based on the acquisition of tumor cells new functions. ADAM proteins, especially protein ADAM9, through their extracellular domain consisting of a disintegrin and metalloprotease activity, have important functions and processes necessary for invasion. However, the mechanisms regulating protein remain largely unknown in cancer pathology. The objective of this work was to evaluate the role of ADAM9 expression in tumor aggressiveness such as cell adhesion, cell migration and angiogenesis and to study the mechanisms regulating this protein expression. Given the fact that hydrogen peroxide is known to induce the expression of ADAM9 protein, the first work aimed to establish the relationship between oxidative stress, adhesion and tumor ADAM9 expression. Hydrogen peroxide induces a dose-dependent increase of both expression and activity of ADAM9 on adenocarcinoma pulmonary cells. Oxidative stress induced ADAM9 expression and activity are mainly supported by the secreted form of ADAM9 protein. In vitro studies have shown that capacity of adhesiveness and invasiveness induced by oxidative stress are mainly mediated by the two forms of ADAM9 protein. In addition, ADAM9 protein expression induces neoangiogenesis through increased production of interleukin 8. This proangiogenic cytokine that interacts with the CXCR2 receptor is able to stimulate neovascularization in vitro studies. Development of a lung adenocarcinoma xenograft model confirmed that ADAM9 protein have an important role on metastasis process and tumor angiogenesis. The study of pharmacological modulation of ADAM9 expression was based on two different pharmacological strategies: the first interacts with different isoforms of ADAM9 using a neutralizing antibody and the second strategy modulate cell transduction mechanism such as SRC protein or protein kinase C (PKC). This work aims to understand the involvement of ADAM9 protein during the process of carcinogenesis, such as tumor invasion induced by oxidative stress and neoangiogenesis

No description available.

Die intestinale Mukosa bildet eine biologisch wichtige Barriere zwischen dem Organismus und den schädigenden Faktoren im intestinalen Lumen. Diese komplexe Aufgabe wird durch eine hochdifferenzierte intestinale Mukosa bewältigt, die eine strukturelle sowie funktionelle intestinale Barriere bildet. Das Ziel der vorliegenden Arbeiten war, ausgewählte Aspekte der Regulations- und Reparaturmechanismen der intestinalen mukosalen Barriere weitergehend zu charakterisieren. Unsere Untersuchungen zeigen, dass das Phospholipid Lysophosphatidsäure (LPA) die intestinale epitheliale Zellmigration stimuliert, die dieser Zellen jedoch inhibiert. Die Modulation der intestinalen Wundheilung durch LPA erfolgt durch einen TGF-b-unabhängigen Mechanismus und wird über einen G-Protein-abhängigen Rezeptor vermittelt, wie wir im Rahmen umfangreicher Untersuchungen zur Signaltransduktion unter Verwendung spezifischer Modulatoren der Signaltransduktion wie Bradykinin, Phorbolester, Pertussistoxin, Suramin und neutralisierender TGF-b-Antikörper belegen konnten. In weiteren Experimenten konnten wir zeigen, dass LPA auch in-vivo einen wundheilungsfördernden Effekt besitzt. Die topische Applikation von LPA in diesem experimentellen Kolitismodell bewirkte einen geringeren Gewichtsverlust sowie ein geringeres Ausmaß an intestinaler Entzündung und Nekrose in-vivo. Diese Untersuchungen legen somit nahe, dass LPA die intestinale epitheliale Wundheilung durch eine Modulation der intestinalen epithelialen Migration und Proliferation durch TGF-b-unabhängige Mechanismen stimuliert. Weitere Untersuchungen beschäftigten sich mit der funktionellen Charakterisierung von Lamina propria T-Zellen (LPT) und peripheren Blut T-Zellen (PBT). Wir konnten zeigen, dass der Zellzyklus von LPT distinkt von PBT reguliert wird. Hierbei spielt der Zellzyklusinhibitor p53 eine zentrale Rolle in der Zellzyklusregulation von LPT. Um Autoimmunität zu verhindern, muss es nach einer Eliminierung des Antigens wieder zu einer Depletion des Pools an Effektor-T-Zellen durch die Aktivierung der Apoptose kommen. Wir konnten zeigen, dass beim Antigen-induzierten Zelltod von LPT der intrinsische Apoptoseweg aktiviert wird und Caspase-8 hierbei eine zentrale Rolle spielt. Physiologischerweise sind Zellzyklus und Apoptose eng miteinander verbunden. In weiteren Versuchen konnten wir jedoch zeigen, dass dies nicht bei LPT der Fall ist und somit die von PBT distinkte Regulation von Zellzyklus und Apoptose mukosaler T-Zellen weiter unterstreichen. Zusammengefasst konnten wir durch ausgewählte Untersuchungen zeigen, dass die intestinale Barriere und ihre funktionelle Beeinflussung eine wesentliche Rolle in der Pathogenese und Therapie intestinaler Entzündungen besitzt. Eine Beeinflussung intestinaler Reparaturprozesse und Modulation abnormer T-Zellen könnte neue Möglichkeiten in der Therapie intestinaler Entzündungen, wie z.B. chronisch entzündlichen Darmerkrankungen bewirken. / The intestinal mucosa protect the host from the potential harmful content of the intestinal lumen. To accomplish this difficult goal, the highly complex mucosa forms an anatomical as well as functional barrier to protect the organism.In this work, we aimed to characterize distinct aspect of the intestinal barrier, focussing on distinct regulation and repair mechanism of the intestinal mucosa. First, we demonstrate, that the phospholipid lysophosphatidic acid (LPA) stimulate the migration of intestinal epithelial cells, but, in contrast, inhibit their proliferation. This effect is mediated by G-protein receptors and is TGF-b-independent, as we could demonstrate in further experiments using bradykinine, phorbole ester, pertussis toxin and suramine to modulate distinct signalling pathways.We then demonstrated, using a well-established animal model of colitis, that LPA enhances intestinal wound healing in-vivo. In detail, the topical application of LPA in TNBS-treated rats reduced weight loss, ameliorate intestinal inflammation and prevented necrosis in the animals. This experiments demonstrate for the first time, that LPA modulates migration and proliferation of intestinal epithelial cells by distinct TGF-b independent pathways. Further experiments aimed to explore functional differences between peripheral blood (PBT) and mucosal T-cells (LPT). We demonstrated, that the cell cycle is distinctively regulated in PBT and LPT, identifying p53 as key regulator of LPT cell cycling. To avoid auto-immunity, the pool of effector T-cells must be depleted by apoptosis, once the antigen has been cleared. We demonstrate, that intrinsic pathway of apoptosis is activated during the antigen-induced cell death in LPT and that caspase-8 activity is required to execute LPT apoptosis. Cell cycle and apoptosis are ultimately linked. However, as we show in further experiments, this is not the case in LPT, underlining the distinct regulation of LPT cell cycle and apoptosis.In conclusion, using various distinct experimental tools, we demonstrate that the intestinal barrier itself and the modulation its function plays a fundamental role in the pathogenesis mucosal inflammation. The data presented in this work may therefore open new therapeutic options in the therapy of intestinal inflammatory disorders, such as inflammatory bowel diseases.